These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33923750)

  • 1. CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade.
    Vackova J; Polakova I; Johari SD; Smahel M
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
    Watanabe T; Ishino T; Ueda Y; Nagasaki J; Sadahira T; Dansako H; Araki M; Togashi Y
    Cancer Sci; 2023 May; 114(5):1859-1870. PubMed ID: 36762794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
    Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
    Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer.
    Bengsch F; Knoblock DM; Liu A; McAllister F; Beatty GL
    Cancer Immunol Immunother; 2017 Dec; 66(12):1609-1617. PubMed ID: 28856392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer.
    Zhang W; Shi L; Zhao Z; Du P; Ye X; Li D; Cai Z; Han J; Cai J
    Cancer Chemother Pharmacol; 2019 May; 83(5):911-920. PubMed ID: 30848330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.
    Devaud C; Westwood JA; Teng MW; John LB; Yong CS; Duong CP; Smyth MJ; Darcy PK; Kershaw MH
    Oncoimmunology; 2014 Nov; 3(11):e963395. PubMed ID: 25941590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice.
    Loser K; Scherer A; Krummen MB; Varga G; Higuchi T; Schwarz T; Sharpe AH; Grabbe S; Bluestone JA; Beissert S
    J Immunol; 2005 May; 174(9):5298-305. PubMed ID: 15843526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
    Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
    J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.
    Giles AJ; Hutchinson MND; Sonnemann HM; Jung J; Fecci PE; Ratnam NM; Zhang W; Song H; Bailey R; Davis D; Reid CM; Park DM; Gilbert MR
    J Immunother Cancer; 2018 Jun; 6(1):51. PubMed ID: 29891009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.
    Li M; Xing S; Zhang H; Shang S; Li X; Ren B; Li G; Chang X; Li Y; Li W
    Oncol Rep; 2016 Mar; 35(3):1329-39. PubMed ID: 26752000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of Regulatory T Cells Activity by Distinct CD80 and CD86 Interactions With CD28/CTLA-4 in Chagas Cardiomyopathy.
    Pinto BF; Medeiros NI; Teixeira-Carvalho A; Fiuza JA; Eloi-Santos SM; Nunes MCP; Silva SA; Fontes-Cal TCM; Belchior-Bezerra M; Dutra WO; Correa-Oliveira R; Gomes JAS
    Front Cardiovasc Med; 2022; 9():750876. PubMed ID: 35665256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells.
    Liu PC; Ssu CT; Tsao YP; Liou TL; Tsai CY; Chou CT; Chen MH; Leu CM
    Arthritis Res Ther; 2020 Mar; 22(1):64. PubMed ID: 32228715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
    Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
    J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.